Columvi (glofitamab-gxbm) / Roche, Biogen - LARVOL DELTA

311: Taking Up the Mantle: Novel Therapeutics in the Treatment of Mantle Cell Lymphoma (HOPA 2026) - "Additionally, this presentation will discuss advances in the treatment of relapsed/refractory MCL with novel agents such as chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies, and non-covalent BTK inhibitors, including a review of key efficacy outcomes, strategies for adverse event management, and considerations for treatment sequencing. UAN: 0465-0000-26-060-L01-P Knowledge or Application Based: Application Learning Objectives: Discuss the frontline use of Bruton's tyrosine kinase inhibitors (BTKis) in mantle cell lymphomaApply patient-specific factors to construct BTKi-based therapeutic plans for individuals with treatment-based therapeutic plans for individuals with treatment-naïve MCLEvaluate efficacy outcomes and toxicity management strategies forregimens incorporating pirtobrutinib, glofitamab, and/or chimeric antigenreceptor T-cell therapy (CAR-T) for treatment of relapsed/refractory MCLFormulate sequencing strategies for..."

Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma

North American Enrollment in Clinical Trials: An Emerging Issue for Regulatory Approval (HOPA 2026) - "In the Asian region, the median OS was not estimable for glofitamab plus gemcitabine and oxaliplatin versus 8.2 months in rituximab plus gemcitabine and oxaliplatin.1 In the rest of the world, the median OS was 21.2 months for glofitamab plus gemcitabine and oxaliplatin versus 27.8 months for rituximab plus gemcitabine and oxaliplatin.1 Even when excluding the OS data, which could be confounded by subsequent therapy, the pooled non-Asian patient data (ie, in United States, Europe, Australia) found glofitamab plus gemcitabine and oxaliplatin did not have significantly longer PFS than with rituximab plus gemcitabine and oxaliplatin.1 The Asian population had more lenalidomide exposure and only 2 of the 131 patients previously received CAR T therapy compared with 19 of 143 patients from the rest of the world.1 In the United States, CAR T therapy is standard of care second- or third-line therapy, whereas there is limited or no access to CAR T therapy in Asia3 Was this an..."

Clinical • B Cell Lymphoma • Breast Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Genito-urinary Cancer • Hematological Malignancies • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Leukemia • Lung Cancer • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • HER-2

Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL) (AACR 2026) - "Abstract is embargoed at this time."

Clinical • Metastases • Monotherapy • P1 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL6

Preclinical immunotoxicity assessment of bispecific antibodies using an ex vivo circulating human whole blood assay (AACR 2026) - "IL-2 was, as expected, not produced in response to either obinutuzumab or alemtuzumab, but was induced to high levels (similar to an agonistic anti-CD28 antibody) in the presence of glofitamab. Neither obinutuzumab nor glofitamab had any effect on complement activation in ID.Flow, whereas alemtuzumab induced increased levels of C3a and C5a.In conclusion, ID.Flow can be used to assess the immunotoxicity and potentially the efficacy of bispecific antibodies with glofitamab as a relevant clinical control."

Bispecific • Preclinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22 • CXCL8 • IFNG • IL2 • IL6 • TNFA

QLS2313, a CD79b/CD20 tri-specific T cell engager with dual-targeting strategy developed as a new therapeutics for the treatment of DLBCL (AACR 2026) - "In vitro, QLS2313 exhibited higher affinity for DLBCL cell lines than JNJ-80948543 (a clinical-stage CD79b/CD20 TCE from Janssen) while demonstrating significantly lower affinity for primary human T cells and Jurkat cells compared to JNJ-80948543 and FDA-approved CD20/CD3 bi-specifics (mosunetuzumab and glofitamab). QLS2313 was well tolerated in a transgenic mice (QW × 4) GLP toxicity study, with the highest non-severely toxic dose (HNSTD) at 30 mg/kg for both intravenous and subcutaneous administration. In conclusion, QLS2313 show superior efficacy, favorable pharmacokinetics and safety profile, which support the clinical development of this novel therapy for DLBCL treatment."

Trispecific • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • CD79B • IL6

A versatile KY-HC-mouse™nanobody platform enabling tumor-anchored, conditionally active 4-1BB bispecific antibodies (AACR 2026) - "CD19×4-1BB (KA-6859) further demonstrates robust in vivo efficacy in hu-PBMC lymphoma models when combined with a CD20×CD3 T-cell engager Glofitamab, with clear tumor growth inhibition at 3 mg/kg KA-6859 plus 0.15mg/kg CD20×CD3 (QW*3), and exhibits favorable pharmacokinetics with sustained serum exposure in mice...CD19×4-1BB (KA-6859) exhibits a transient ExpiCHO-S expression yield of ~393 mg/L and a favorable pharmacokinetic profile in C57BL/6 mice, with terminal half-lives of approximately 16-21 days after i.v. dosing and ~10 days after s.c. dosing, and an s.c. bioavailability of ~82%. KA-6859 also displays high thermal stability and good overall stability, indicating favorable developability.Together, these data position the KY-HC-mouse™ 4-1BB nanobody platform as a versatile foundation for next-generation, tumor-anchored 4-1BB bispecifics and multispecifics, and for future combinations with checkpoint inhibitors in solid and hematologic malignancies."

Bispecific • IO biomarker • Preclinical • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • CD20 • CDH17 • CLDN18 • TNFRSF9

Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab. (PubMed, Cancers (Basel)) - "LAG3 rs870849 may be a prognostic response marker in R/R DLBCL treated with glofitamab."

IO biomarker • Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • CTLA4 • LAG3

Clinical predictors of cytokine release syndrome in non-single chain CD3 directed therapies among cancer patients (AACR 2026) - "20 patients were identified with median age of 67 years. 30% were male and 70% were female. 35% received tarlatamab, 30% got glofitamab, 10% got talquetamab and epcoritamab each, 1 patient got mosunetuzumab and linvoseltamab."

Clinical • Cytokine release syndrome • Oncology

Gut Microbiome in DLBCL Treated With Glofitamab (clinicaltrials.gov) - P=N/A | N=30 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital

New trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A universal multi-receptor NK cell platform engineered for synergistic combination with antibody and T-cell engager therapies (AACR 2026) - "This dual-activation system allows PluraliNK cells to respond to CD3- or CD16-mediated signals and to pair with diverse mAbs or TCEs without further modification. PluraliNK cells showed potent cytotoxicity across hematologic and solid tumor models when combined with approved mAbs (rituximab, trastuzumab) or TCEs (blinatumomab, glofitamab, elranatamab), consistently outperforming mAb/TCE monotherapy or unmodified NK cells. This universal NK-cell platform enables multiantigen targeting and integration with existing mAbs and TCEs, addressing tumor heterogeneity and immune escape without requiring antigen-specific CAR redesign. A first-in-human clinical trial of PluraliNK cells with antibody therapy has been initiated."

First-in-human • Oncology • Solid Tumor • FCGR3A • IL15

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma (clinicaltrials.gov) - P1 | N=39 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • CD20 • TNFA

PREDOMINANCE OF CD4+ T-CELLS IS ASSOCIATED WITH IMPROVED OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL (EBMT 2026) - "Among patients who received bridging therapy (n=64), the most frequently used regimen was R-DHAC (19, 29.7%), followed by radiotherapy (13, 20.3%), R-Holoxan-etoposide (12, 18.8%), R-GEMOX (5, 7.8%), R-ICE (6, 9.4%) and glofitamab (2, 3.1%). Higher CD4+/CD8+ ratios with predominance of CD4+ T-lymphocytes were associated with better response outcomes and increased severity of CRS and incidence of ICANS. Older age and specific bridging regimens influenced lymphocyte CD4+ and CD8+ distributions. These findings support the potential prognostic relevance of CD4+/CD8+ ratios and lymphocytes subsets in patients undergoing CAR-T therapy."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD4 • CD8

ALLOGENEIC TRANSPLANTATION AFTER FAILURE OF CAR-T CELLS AND EXPOSURE TO BISPECIFIC ANTIBODIES: FEASIBILITY, SAFETY AND SURVIVAL OUTCOMES (EBMT 2026) - "Prior CAR-T product were axicabtagene ciloleucel (n=8) or tisagenlecleucel (n=11); BsAb was glofitamab (n=18) or epcoritamab (n=1)...Uncommon toxicities included one steroid-responsive hemolytic anemia, one anti-GM2-ganglioside IgM-positive acute demyelinating polyneuropathy diagnosed 10 months after alloSCT, successfully managed with intravenous immunoglobulins with complete recovery, and one case of iatrogenic encephalopathy on a likely microangiopathic basis, possibly related to cyclosporine... AlloSCT consolidation after CAR-T cells and BsAb exposure is feasible in selected, fit and responding patients, providing durable disease control with acceptable toxicity. Despite heavy pre-treatment, no unexpected safety signals emerged, with relatively low GvHD rates across donor type, and limited transplant-related mortality. In conclusion, alloSCT consolidation should be offered to all eligible patients failing both T-cell redirecting strategies, and carefully evaluated..."

Bispecific • CAR T-Cell Therapy • Clinical • Acute Graft versus Host Disease • B Cell Lymphoma • Chronic Graft versus Host Disease • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

EFFICACY AND SAFETY OF CD20XCD3 BISPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMAS: A SYSTEMATIC REVIEW AND META-ANALYSIS (EBMT 2026) - " We conducted a systematic review and meta-analysis to evaluate efficacy and safety of CD20xCD3 BsAbs (mosunetuzumab, epcoritamab, odronextamab, and glofitamab) in patients with R/R iNHL. CD20xCD3 bispecific antibodies demonstrate substantial clinical activity and induce high, durable complete response rates in heavily pretreated patients with R/R iNHL, including those with high-risk features. The safety profile is manageable, with CRS being the most common adverse event of special interest, although predominantly low-grade. These findings support BsAbs as a new, effective therapeutic class for indolent lymphomas."

Bispecific • Retrospective data • Review • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

IMPACT OF TREATMENT SEQUENCE OF GLOFITAMAB AND CAR-T THERAPY ON EFFICACY, SURVIVAL, AND TARGET ANTIGEN EXPRESSION IN RELAPSED/REFRACTORY B-NHL (EBMT 2026) - "The sequence of immunotherapy may influence survival, with CAR-T followed by bsAb potentially providing longer PFS. Bispecific antibody therapy is associated with higher rates of CD20 antigen loss compared to CAR-T–induced CD19 loss, which may contribute to resistance. Patients who initially respond to one immunotherapy may still benefit from the alternative modality upon relapse, supporting sequential treatment strategies in R/R B-NHL."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Non-Hodgkin Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD20

REAL-WORLD EVIDENCE FOR THE SAFETY AND EFFICACY OF GLOFITAMAB COMBINED WITH CAR-T THERAPY IN RELAPSED/REFRACTORY B-CELL LYMPHOMA (EBMT 2026) - P1 | "This real-world study demonstrates that Glofitamab combined with CAR-T therapy achieves superior PFS and OS in r/r B-NHL. Single-cell data reveal that the clinical benefit correlates with a sustained JAK/STAT survival circuit in T cells, specifically driven by IL-15 from monocytes/granulocytes. Supported by functional data showing enhanced T cell cytotoxicity, Tem differentiation, and immunological synapse formation, these findings highlight Glofitamab combination therapy as a key strategy for enhancing long-term T-cell persistence and immune surveillance post-CAR-T therapy."

CAR T-Cell Therapy • Clinical • HEOR • Real-world • Real-world evidence • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD20 • IL15 • LAMP1

SAFE DELIVERY OF BISPECIFIC ANTIBODIES AT CHRISTIE PRIVATE CARE: SERVICE IMPLEMENTATION AND EARLY SAFETY OUTCOMES (EBMT 2026) - "The cohort included 12 patients with relapsed/refractory multiple myeloma treated with Teclistamab or Talquetamab, and 1 patient with relapsed Burkitt's lymphoma treated with Glofitamab. Bi-specific antibodies were delivered safely within The Christie Private Care using structured monitoring pathways and early-intervention protocols. CRS events were mild and manageable with standard therapies, including dexamethasone and tocilizumab where required.Recurrent Hospitalization rates were low, and overall treatment delivery remained feasible and well-tolerated. These findings support the safe provision of advanced immunotherapies in a private-care setting."

Bispecific • Clinical • Burkitt Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Septic Shock

EFFICACY AND SAFETY OF CD20XCD3 BISPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMAS: A SYSTEMATIC REVIEW AND META-ANALYSIS (EBMT 2026) - " We conducted a systematic review and meta-analysis to evaluate efficacy and safety of CD20xCD3 BsAbs (mosunetuzumab, epcoritamab, odronextamab, and glofitamab) in patients with R/R iNHL. CD20xCD3 bispecific antibodies demonstrate substantial clinical activity and induce high, durable complete response rates in heavily pretreated patients with R/R iNHL, including those with high-risk features. The safety profile is manageable, with CRS being the most common adverse event of special interest, although predominantly low-grade. These findings support BsAbs as a new, effective therapeutic class for indolent lymphomas."

Bispecific • Retrospective data • Review • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

IMPACT OF TREATMENT SEQUENCE OF GLOFITAMAB AND CAR-T THERAPY ON EFFICACY, SURVIVAL, AND TARGET ANTIGEN EXPRESSION IN RELAPSED/REFRACTORY B-NHL (EBMT 2026) - "The sequence of immunotherapy may influence survival, with CAR-T followed by bsAb potentially providing longer PFS. Bispecific antibody therapy is associated with higher rates of CD20 antigen loss compared to CAR-T–induced CD19 loss, which may contribute to resistance. Patients who initially respond to one immunotherapy may still benefit from the alternative modality upon relapse, supporting sequential treatment strategies in R/R B-NHL."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Non-Hodgkin Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD20

MANAGEMENT OF RELAPSED/REFRACTORY (R/R) B-NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES (BSABS). A SINGLE CENTER EXPERIENCE (EBMT 2026) - "Glofitamab, epcoritamab, and mosunetuzumab are all anti-CD20/anti-CD3 BsAbs, showing comparable efficacy and class distinct safety profiles. Anti-CD20/anti-CD3 BsAbs have already entered routine clinical practice for the treatment of R/R B-NHL. The majority of our patients benefited from BsAbs. Infections, nonetheless, remain a substantial challenge and a major cause of mortality."

Bispecific • Clinical • CNS Disorders • Diffuse Large B Cell Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Richter's Syndrome • Septic Shock

CLINICAL OUTCOMES AND PREDICTORS OF INTENSIVE CARE ADMISSION IN LYMPHOMA PATIENTS TREATED WITH BISPECIFICS (EBMT 2026) - " The study included 62 patients, 32 women (51.6%) and 30 men (48.4%), who received odronextamab (n=14, 22.6%), glofitamab (n=13, 20.9%), epcoritamab (n=16, 25.8%), or mosunetuzumab (n=19, 30.7%)...ICU-admitted patients received significantly more doses of tocilizumab (χ²=6.7, p=0.03), but not steroids (χ²=8.1, p=0.4)... No significant differences in treatment-related toxicity were seen between ICU and ward patients. Mortality was mostly due to disease progression, with one therapy-related death in a non-ICU candidate. Outpatient administration appears feasible, as complications were infrequent and mild."

Bispecific • Clinical • Clinical data • Critical care • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Septic Shock

PREDOMINANCE OF CD4+ T-CELLS IS ASSOCIATED WITH IMPROVED OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL (EBMT 2026) - "Among patients who received bridging therapy (n=64), the most frequently used regimen was R-DHAC (19, 29.7%), followed by radiotherapy (13, 20.3%), R-Holoxan-etoposide (12, 18.8%), R-GEMOX (5, 7.8%), R-ICE (6, 9.4%) and glofitamab (2, 3.1%). Higher CD4+/CD8+ ratios with predominance of CD4+ T-lymphocytes were associated with better response outcomes and increased severity of CRS and incidence of ICANS. Older age and specific bridging regimens influenced lymphocyte CD4+ and CD8+ distributions. These findings support the potential prognostic relevance of CD4+/CD8+ ratios and lymphocytes subsets in patients undergoing CAR-T therapy."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD4 • CD8

ALLOGENEIC TRANSPLANTATION AFTER FAILURE OF CAR-T CELLS AND EXPOSURE TO BISPECIFIC ANTIBODIES: FEASIBILITY, SAFETY AND SURVIVAL OUTCOMES (EBMT 2026) - "Prior CAR-T product were axicabtagene ciloleucel (n=8) or tisagenlecleucel (n=11); BsAb was glofitamab (n=18) or epcoritamab (n=1)...Uncommon toxicities included one steroid-responsive hemolytic anemia, one anti-GM2-ganglioside IgM-positive acute demyelinating polyneuropathy diagnosed 10 months after alloSCT, successfully managed with intravenous immunoglobulins with complete recovery, and one case of iatrogenic encephalopathy on a likely microangiopathic basis, possibly related to cyclosporine... AlloSCT consolidation after CAR-T cells and BsAb exposure is feasible in selected, fit and responding patients, providing durable disease control with acceptable toxicity. Despite heavy pre-treatment, no unexpected safety signals emerged, with relatively low GvHD rates across donor type, and limited transplant-related mortality. In conclusion, alloSCT consolidation should be offered to all eligible patients failing both T-cell redirecting strategies, and carefully evaluated..."

Bispecific • CAR T-Cell Therapy • Clinical • Acute Graft versus Host Disease • B Cell Lymphoma • Chronic Graft versus Host Disease • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

THIOTEPA, CYCLOPHOSPHAMIDE AND FLUDARABINE CONDITIONING REGIMEN FOR ADULT PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: IMPACT OF DONOR MISMATCH ON OUTCOME (EBMT 2026) - "Median number of lines before transplant were 3 (range 1-10); 8 (23%) pts received autologous stem cell transplant, 6 (18%) pts CAR-T (3 tisagenlecleucel, 1 brexucabtagene autoleucel, 1 axicabtagene ciloleucel) and 6 (18%) bispecific antibodies (4 glofitamab, 2 mosunetuzumab). Our data highlight the efficacy of TCF conditioning for disease control in heavily pretreated lymphomas, with 1-year PFS and OS of 66% and 71% respectively. HSCT from mismatched donors had higher complications rate (mainly GVHD, despite the prevalent use of PT-Cy GVHD prophylaxis platform) and a tendency of lower 1-year OS."

Clinical • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Richter's Syndrome • T Cell Non-Hodgkin Lymphoma • Transplantation

Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO. (ASCO 2025) - P3 | "We present updated efficacy and safety of Glofit-GemOx vs rituximab (R)-GemOx in pts with R/R DLBCL after ≥1 LOT from the Phase 3 STARGLO trial (NCT04408638), including landmark analyses of pts in complete remission (CR)...After obinutuzumab pretreatment, glofitamab was given in Cycle (C) 1 as weekly step-up doses (2.5/10mg) then 30mg target dose every 21 days from C2 Day 1... With 2 yrs follow-up, Glofit-GemOx sustained a clinically meaningful benefit in OS and PFS vs R-GemOx in ASCT-ineligible pts with R/R DLBCL, with most (82%) pts in CR at EOT still in remission. The safety profile was consistent with known risks of each drug. The updated analyses support the long-lasting remissions and maintained OS benefit in pts with R/R DLBCL treated with fixed duration Glofit-GemOx."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20